CEN501

CEN501is a nasal immunotherapy kit developed by NeuCenBiomed. for the treatment of allergic rhinitis

 

Immunotherapy is the long-term and planned introduction of allergens into the body to improve the patient's own immunity to achieve the desensitization effect.

 

CEN501 has the following features:

New route of administration

Less side effects

Lower frequency of medication

Compared with the existing Immunotherapy on the market, including subcutaneous injection and sublingual tablet, CEN501 provides a new option of Immunotherapy treatment with comparable efficacy but is safer and more convenient, and patients will be more likely to complete the course of treatment

 

CEN501 utilizes allergen drugs already on the market through a new route of administration, andis expected to shorten the drug development process.  It is expected to apply for a clinical trial review (IND) in Q3 of 2022 and targets to enter directly into Phase III clinical trials.